Johnson & Johnson Innovation-JJDC Inc.

06/16/2026 | Press release | Archived content

Beyond remission: deep healing in autoimmune disease

Treatment of chronic inflammatory disease has advanced from symptom management to disease control, yet many patients still face incomplete responses, relapse, and treatment dependence. Subclinical inflammation and tissue injury often persist-driving cumulative damage and impacting patients' quality of life.

J&J invites you to an event focused on the next paradigm shift: moving beyond inflammation control to enable "deep healing," where tissue structure, barrier integrity, and homeostatic set points are restored to support durable, meaningful outcomes for patients.

While controlling inflammation aids healing, deeper recovery requires more than just anti-inflammatory approaches. Complementary pathways with a direct role in repair are needed to promote sustained and durable remission. Several emerging areas of biology focused on restoration of epithelial barriers and/or modulation of peripheral neuro-immune signaling pathways, are emerging as novel opportunities.

View the recording as J&J experts and guest speakers discuss promising innovations in this field and how we might collaborate across the European life sciences ecosystem to bring these innovations to patients.

The program is tailored to academic innovators and startups in autoimmune disease who are interested in collaborative opportunities related to repair in chronic inflammatory conditions including gut, skin, lung and rheumatic conditions.

Johnson & Johnson Innovation-JJDC Inc. published this content on June 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 25, 2026 at 14:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]